Semler Scientific, Inc. Q2 FY2021 Earnings Call

· Earnings call transcript and AI-powered summary

  • Quarter Highlights: Semler Scientific reported record-breaking financials in Q2 2021:
    • Revenue up 125% YoY to $14.3 million (Q2 2020: $6.4 million).
    • Pretax net income increased 554% YoY to $6.5 million (Q2 2020: $1 million).
    • Net income grew 522% YoY to $6.7 million (Q2 2020: $1.1 million).
    • Cash balance at quarter end was $28.5 million.
    • Net income per share: $1.00 basic / $0.83 diluted vs. $0.16/$0.13 last year.
    • Headcount increased to 115 from 103 in Q1 2021.
  • Revenue Growth Drivers: Increased orders from existing insurance and health risk assessment (HRA) customers as well as new customer acquisitions. QuantaFlo product continues to lead demand.
  • Expense Overview: Operating expenses rose 45% YoY to $7.8 million, largely controlled despite strong sales growth.
  • Cost Efficiency: Improved gross margin of 93%. Q1 cost of revenue included a one-time inventory adjustment, positively impacting Q2 comparative margins.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and welcome to the Semler Scientific Second Quarter 2021 Financial Results Conference Call. Please note, this event is being recorded. Before we begin, Semler Scientific would like to remind you that this conference call may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, intend, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here. These risks include continued uncertainty due to the evolving COVID-19 pandemic, risks associated with Semler Scientific's recent investments in entities with potential complementary products and new distribution arrangements along with other risks associated with Semler Scientific's business. Doug Murphy-Chutorian: Good afternoon, everybody, and thank you for joining us for our second quarter results call. I'd like to introduce Dennis Rosenberg, our Chief Marketing Officer, who will begin the call for us today. Dennis? Dennis Rosenberg: Thanks, Doug. We always like to begin our calls with a reminder about Semler's strategy. Semler is a company that provides technology solutions to improve the clinical effectiveness and efficiency of health care providers. Our mission is to develop, manufacture and market innovative products that assist our customers in evaluating and treating chronic diseases. We believe that

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional